VLX600
Code | Size | Price |
---|
TAR-T8500-1mL | 1 mL * 10 mM (in DMSO) | £109.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T8500-5mg | 5mg | £109.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T8500-10mg | 10mg | £132.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T8500-25mg | 25mg | £197.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T8500-50mg | 50mg | £282.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T8500-100mg | 100mg | £432.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
VLX600 is an iron-chelating oxidative phosphorylation (OXPHOS) inhibitor, is a cell-permeable anticancer agent. It acts by reducing mitochondrial oxidative phosphorylation in tumor cells.
CAS:
327031-55-0
Formula:
C17H15N7
Molecular Weight:
317.356
Pathway:
Autophagy; Metabolism; Apoptosis
Purity:
1
SMILES:
CC(=N/Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1
Target:
OXPHOS; Mitochondrial Metabolism; Autophagy
References
Arun Kanakkanthara , Kiran Kurmi , Thomas L Ekstrom, et al.BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents[1].Cancer Res. 2019 Dec 1;79(23):5920-5929.
Karlsson H, et al. A novel tumor spheroid model identifies selective enhancement of radiation by an inhibitor of oxidative phosphorylation. Oncotarget. 2019 Sep 3;10(51):5372-5382.
Xiaonan Zhang , M?rten Frykn?s , Emma Hernlund,et al. Induction of Mitochondrial Dysfunction as a Strategy for Targeting Tumour Cells in Metabolically Compromised Microenvironments[J].Nat Commun. 2014;5:3295.